Eric A. Ariazi, PhD, is a distinguished Translational Medicine Scientist with 25+ years of experience spanning academia and industry. Presently, he lends his deep expertise in biomarkers for epigenetic compounds as a consultant for Volition. Dr. Ariazi’s interest in epigenetics began at Fox Chase Cancer Center where he discovered that the master transcription factor estrogen receptor-α also plays a novel role in regulating DNA methylation. Transitioning to industry, Dr. Ariazi played a pivotal role at Freenome, spearheading the development of high-depth cfDNA methylation sequencing assays for blood-based cancer detection, now key IP of the company. His tenure at ORIC Pharmaceuticals was marked by pioneering clinical biomarker strategies, notably for a PRC2 inhibitor utilizing Volition’s innovative Nu.Q™ nucleosome assays. Dr. Ariazi is an author on 31 scientific publications, including reviews and a book chapter, as well as an inventor on 4 granted patents.